Al-Khazali, Haidar M.
Christensen, Rune H.
Chaudhry, Basit Ali
Melchior, Anna G.
Ashina, Messoud
Burstein, Rami
Ashina, Håkan
Funding for this research was provided by:
Copenhagen University
Article History
Received: 11 February 2024
Accepted: 1 April 2024
First Online: 17 April 2024
Declarations
:
: The study protocol was approved by the ethics committee of Capital Region, Denmark, and written informed consent was obtained from all participants.
: H.M.A. reports personal fees from Pfizer, outside of the submitted work. R.B. reports research support received from Allergan, Dr. Reddy’s Laboratories, Eli Lilly, and Teva, outside of the submitted work. In addition, R.B. has received honoraria, acted as a consultant or advisory board member for Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Biohaven, CGRP Diagnostics, Dr. Reddy’s Laboratories, ElectroCore, Eli Lilly, GlaxoSmithKline, Merck, Pernix, Teva, and Trigemina. R.B. also reports receiving CME fees from Healthlogix, Medlogix, and WebMD/Medscape, and holds patents for several products, including (9061025, 11732265.1, 10806890, US2021-0015908, WO21007165, US2021-0128724, WO21005497). M.A. reports receiving personal fees from AbbVie, Amgen, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals, outside of the submitted work. M.A. also serves as an Associate editor of Brain and The Journal of Headache and Pain. R.B. is a reviewer for the National Institute of Neurological Disorders and Stroke (NINDS) and holds stock options in Allay Lamp and Percept, outside of the submitted work. H.A. reports personal fees from Lundbeck and Teva, outside of the submitted work. The remaining authors declare no competing interests.